"Digoxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
| Descriptor ID |
D004077
|
| MeSH Number(s) |
D04.210.500.155.580.130.500.436 D04.210.500.155.580.130.688 D09.408.180.261.436
|
| Concept/Terms |
Digoxine Nativelle- Digoxine Nativelle
- Nativelle, Digoxine
- Hemigoxine Nativelle
- Nativelle, Hemigoxine
Lanoxin- Lanoxin
- Lanoxin-PG
- Lanoxin PG
- Lenoxin
|
Below are MeSH descriptors whose meaning is more general than "Digoxin".
Below are MeSH descriptors whose meaning is more specific than "Digoxin".
This graph shows the total number of publications written about "Digoxin" by people in this website by year, and whether "Digoxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2007 | 0 | 3 | 3 |
| 2009 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Digoxin" by people in Profiles.
-
Khodabande A, Ghassemi F, Asadi Amoli F, Riazi-Esfahani H, Mahmoudzadeh R, Mehrpour M, Valipour N. Ocular safety of repeated intravitreal injections of Carboplatin and Digoxin: A preclinical study on the healthy rabbits. Pharmacol Res Perspect. 2021 08; 9(4):e00814.
-
Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015 Jun 30; 65(25):2691-8.
-
Subzposh F, Gupta A, Hankins SR, Eisen HJ. Management of ACCF/AHA Stage A and B patients. Cardiol Clin. 2014 Feb; 32(1):63-71, viii.
-
Feitell S, Hankins SR, Eisen HJ. Adjunctive therapy and management of the transition of care in patients with heart failure. Cardiol Clin. 2014 Feb; 32(1):163-74, x.
-
Isezuo SA, Musa AA, Saidu SA. Multiple embolisations in rheumatic heart disease: a case report. West Afr J Med. 2009 Jul-Aug; 28(4):274-6.
-
Mayson SE, Greenspon AJ, Adams S, Decaro MV, Sheth M, Weitz HH, Whellan DJ. The changing face of postoperative atrial fibrillation prevention: a review of current medical therapy. Cardiol Rev. 2007 Sep-Oct; 15(5):231-41.
-
Saltzman HE, Sharma K, Mather PJ, Rubin S, Adams S, Whellan DJ. Renal dysfunction in heart failure patients: what is the evidence? Heart Fail Rev. 2007 Mar; 12(1):37-47.
-
Hamad E, Mather PJ, Srinivasan S, Rubin S, Whellan DJ, Feldman AM. Pharmacologic therapy of chronic heart failure. Am J Cardiovasc Drugs. 2007; 7(4):235-48.
-
Kowey PR. A review of carvedilol arrhythmia data in clinical trials. J Cardiovasc Pharmacol Ther. 2005 Jun; 10 Suppl 1:S59-68.
-
Eyal D, Molczan KA, Carroll LS. Digoxin toxicity: pediatric survival after asystolic arrest. Clin Toxicol (Phila). 2005; 43(1):51-4.